Patents by Inventor Philip J. Percel

Philip J. Percel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pulsatile release histamine H2 antagonist dosage form
    Publication number: 20040131682
    Abstract: A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration—time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
    Type: Application
    Filed: October 20, 2003
    Publication date: July 8, 2004
    Inventors: Philip J. Percel, Nehal H. Vyas, Krishna S. Vishnupad, Gopi M. Venkatesh
  • Pulsatile release histamine H2 antagonist dosage form
    Patent number: 6663888
    Abstract: A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: December 16, 2003
    Assignee: Eurand Pharmaceuticals Ltd.
    Inventors: Philip J. Percel, Nehal H. Vyas, Krishna S. Vishnupad, Gopi M. Venkatesh
  • Pulsatile release histamine H2 antagonist dosage form
    Publication number: 20030113374
    Abstract: A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
    Type: Application
    Filed: January 25, 2002
    Publication date: June 19, 2003
    Inventors: Philip J. Percel, Nehal H. Vyas, Krishna S. Vishnupad, Gopi M. Venkatesh